$GALT Recent Headlines Six stocks to watch 4:27 p.m.

New Post Public Reply Private Reply Replies (0) Message Board

Sep 2, 2014 at 10:11 AM

$GALT Recent Headlines

Six stocks to watch 4:27 p.m. Feb. 26, 2014 - The Trading Deck

Biotechs With Insider Buying 2:16 p.m. Aug. 22, 2014 - Seeking Alpha
Wedbush Securities' Liana Moussatos On The Art And Science Of Picking Biotechs With Upside 12:01 p.m. Aug. 22, 2014 - Seeking Alpha
10-Q: GALECTIN THERAPEUTICS INC 5:19 p.m. Aug. 7, 2014 - Edgar Online - (EDG = 10Q, 10K)
Galectin gets notice of allowance for patent app related to GR-MD-02 10:20 a.m. Aug. 5, 2014 - Seeking Alpha
Why Galectin Therapeutics (GALT) Stock Is Plummeting Today 1:04 p.m. July 29, 2014 - TheStreet.com
Galectin Drug is a Fatty Liver Flop 10:26 a.m. July 29, 2014 - TheStreet.com
Galectin Pays Stock Promoters to Entice Retail Investors 12:34 p.m. July 28, 2014 - TheStreet.com
Galectin Therapeutics: Why This Penny Stock Dressed Up By Stock Promoters Is A Short 10:32 a.m. July 28, 2014 - Seeking Alpha
10-Q: GALECTIN THERAPEUTICS INC 4:34 p.m. May 13, 2014 - Edgar Online - (EDG = 10Q, 10K)
Do The Math: Ram Selvaraju On The Appeal Of Biotechs In Orphan Diseases 8:48 a.m. April 23, 2014 - Seeking Alpha
Galectin Therapeutics Rises on GR-MD-02 Update - Analyst Blog 4:45 p.m. April 21, 2014 - Zacks.com
Galectin Therapeutics (GALT) Falls: Stock Goes Down 11.3% - Tale of the Tape 8:38 a.m. April 2, 2014 - Zacks.com
Galectin Therapeutics, Inc. (GALT) in Focus: Stock Moves Up 8.84% - Tale of the Tape 8:44 a.m. March 26, 2014 - Zacks.com
10-K: GALECTIN THERAPEUTICS INC 5:05 p.m. March 21, 2014 - Edgar Online - (EDG = 10Q, 10K)
Fatty Liver Disease Should Keep Stocks Moving In 2014 5:02 p.m. March 7, 2014 - Investors Business Daily
Why La Jolla Pharma Has Very Favorable Risk/Reward 4:52 p.m. Feb. 5, 2014 - Seeking Alpha
Intercept’s Fibrosis Success Gives Galectin High Hope 1:02 p.m. Jan. 28, 2014 - Wall St. Cheat Sheet
Liver Drug Race: Intercept Pharma Vs. Rivals 8:24 p.m. Jan. 26, 2014 - Seeking Alpha
Update on GALT's GR-MD-02 - Analyst Blog 7:50 p.m. Jan. 23, 2014 - Zacks.com
Galectin Therapeutics falls after big rally 3:25 p.m. Jan. 13, 2014 - Seeking Alpha

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Galectin Therapeutics, Inc. (GALT) To Contact The Firm 9:15 p.m. Aug. 29, 2014 - PR Newswire - PRF
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 11:16 a.m. Aug. 28, 2014 - PR Newswire - PRF
Deadline in Lawsuit for Investors in Galectin Therapeutics Inc. (GALT) Shares Over Alleged Securities Laws Violations Announced by Shareholders Foundation 10:15 a.m. Aug. 26, 2014 - GlobeNewswire
EQUITY ALERT: Rosen Law Firm Reminds Galectin Therapeutics, Inc. Investors of Important Class Action Deadline -- GALT 1:03 p.m. Aug. 25, 2014 - GlobeNewswire
Hagens Berman Advises Investors in Galectin Therapeutics, Inc. of the Sept. 29, 2014 Lead Plaintiff Class-Action Deadline 9:01 a.m. Aug. 25, 2014 - GlobeNewswire
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Galectin Therapeutics, Inc. (GALT) to Contact the Firm 9:15 a.m. Aug. 23, 2014 - Marketwire
GALECTIN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit against Galectin Therapeutics Inc. 10:00 p.m. Aug. 22, 2014 - BusinessWire - BZX
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Galectin Therapeutics Inc. to Contact Brower Piven Before the September 29, 2014 Lead Plaintiff Deadline in Class Action Lawsuit -- GALT 9:50 p.m. Aug. 22, 2014 - GlobeNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investments in Galectin Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline -- GALT 1:38 p.m. Aug. 22, 2014 - GlobeNewswire
Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Galectin Therapeutics Inc. 1:37 p.m. Aug. 22, 2014 - BusinessWire - BZX
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 12:29 p.m. Aug. 20, 2014 - GlobeNewswire
GALECTIN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Galectin Therapeutics Inc. - GALT 10:00 p.m. Aug. 15, 2014 - GlobeNewswire
Law Offices of Marc S. Henzel Announces Securities Class Action Periods 9:11 a.m. Aug. 12, 2014 - PR Newswire - PRF
Technical Roundup on Biotech Stocks -- Medivation, Ironwood Pharma, Momenta Pharma, Galectin Therapeutics, and PDL BioPharma 8:50 a.m. Aug. 12, 2014 - PR Newswire - PRF
Galectin Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors 5:29 p.m. Aug. 11, 2014 - BusinessWire - BZX
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Galectin Therapeutics Inc. To Contact Brower Piven Before The September 29, 2014 Lead Plaintiff Deadline In Class Action Lawsuit 9:02 a.m. Aug. 10, 2014 - BusinessWire - BZX
Lifshitz & Miller Law Firm Announces Investigation of Cobalt International Energy, Inc., DreamWorks Animation SKG, Inc., Galectin Therapeutics, Inc., Impax Laboratories, Inc., Peoples Federal Bancshares, Inc. and Siuslaw Financial Group, Inc. 2:15 p.m. Aug. 8, 2014 - PR Newswire - PRF
Galectin Therapeutics Reports Second Quarter 2014 Financial Results 5:30 p.m. Aug. 7, 2014 - GlobeNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Galectin Therapeutics, Inc. and Certain Officers -- GALT 10:58 a.m. Aug. 7, 2014 - GlobeNewswire
Lieff Cabraser Announces Class Action Litigation Against Galectin Therapeutics Inc. - GALT 12:21 a.m. Aug. 7, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....